Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection

Cytokine

Volumn 82, Issue , 2016, Pages 38-51

  Samarani, Suzanne ^a,b,c,e   Allam, Ossama ^a,b,c,e   Sagala, Patrick ^a,b,c,e   Aldabah, Zainab ^a,b,c,e   Jenabian, Mohammad Ali ^f   Mehraj, Vikram ^g   Tremblay, Cécile ^c,d,e   Routy, Jean Pierre ^g   Amre, Devendra ^b,c,e   Ahmad, Ali ^a,b,c,e  

^a Laboratory of Innate Immunity   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c Infectiology and Immunology ^*  (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

AIDS; CART; Caspase 1; HIV 1; IL 18; IL 18BP; IL 37; Inflammasome

Indexed keywords

ANTIVIRUS AGENT; CRYOPYRIN; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 RECEPTOR BETA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 37; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; INTERLEUKIN-18 BINDING PROTEIN; SIGNAL PEPTIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; FEEDBACK SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PYROPTOSIS; RETINOPATHY; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; UBIQUITINATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-18;

EID: 84958225199     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.01.006     Document Type: Article

References (139)

1. Dinarello C.A. Overview of the interleukin-1 family of ligands and receptors. Semin. Immunol. 2013, 25(6):389-393. (Epub 2013 November 23). 10.1016/j.smim.2013.10.001.
2. Nakamura K., Okamura H., Wada M., Nagata K., Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect. Immun. 1989, 57:590-595.
3. Okamura H., Nagata K., Komatsu T., Tanimoto T., Nukata Y., Tanabe F., Akita K., Torigoe K., Okura T., Fukuda S., et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect. Immun. 1995, 63(10):3966-3972.
4. Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J. Leukoc. Biol. 2003, 73(2):213-224. (Review).
5. Dinarello C. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 2007, 27:98-114.
6. Sedimbi S.K., Hägglöf T., Karlsson M.C. IL-18 in inflammatory and autoimmune disease. Cell. Mol. Life Sci. 2013, 70(24):4795-4808. (Epub 2013 July 27). 10.1007/s00018-013-1425-y.
7. Sekiyama A., Ueda H., Kashiwamura S., Nishida K., Kawai K., Teshima-kondo S., Rokutan K., Okamura H. IL-18; a cytokine translates a stress into medical science. J. Med. Invest. 2005, 52(Suppl.):236-239.
8. Sugama S., Conti B. Interleukin-18 and stress. Brain Res. Rev. 2008, 58(1):85-95. (Epub 2007 November 28). 10.1016/j.brainresrev.2007.11.003.
9. Ghayur T., Banerjee S., Hugunin M., Butler D., Herzog L., Carter A., Quintal L., Sekut L., Talanian R., Paskind M., Wong W., Kamen R., Tracey D., Allen H. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997, 386(6625):619-623.
10. Gu Y., Kuida K., Tsutsui H., Ku G., Hsiao K., Fleming M.A., Hayashi N., Higashino K., Okamura H., Nakanishi K., Kurimoto M., Tanimoto T., Flavell R.A., Sato V., Harding M.W., Livingston D.J., Su M.S. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997, 275(5297):206-209.
11. Fantuzzi G., Reed D.A., Dinarello C.A. IL-12-induced IFNg is dependent on caspase-1 processing of the IL-18 precursor. J. Clin. Invest. 1999, 104(6):761-767. 10.1172/JCI7501.
12. Guo H., Callaway J.B., Ting J.P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 2015, 21(7):677-687. (Epub 2015 June 29). 10.1038/nm.3893.
13. Qu Y., Franchi L., Nunez G., Dubyak G.R. Non-classical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 2007, 179(3):1913-1925.
14. Lage S.L., Longo C., Branco L.M., da Costa T.B., Buzzo Cde L., Bortoluci K.R. Emerging concepts about NAIP/NLRC4 inflammasomes. Front. Immunol. 2014, 5(2):309. (eCollection 2014). 10.3389/fimmu.2014.00309.
15. Kim M.L., Chae J.J., Park Y.H., De Nardo D., Stirzaker R.A., Ko H.J., Tye H., Cengia L., DiRago L., Metcalf D., Roberts A.W., Kastner D.L., Lew A.M., Lyras D., Kile B.T., Croker B.A., Masters S.L. Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β. J. Exp. Med. 2015, 212(6):927-938. (Epub 2015 May 25). 10.1084/jem.20142384.
16. Liu S.B., Mi W.L., Wang Y.Q. Research progress on the NLRP3 inflammasome and its role in the central nervous system. Neurosci. Bull. 2013, 29(6):779-787. (Epub 2013 March 20). 10.1007/s12264-013-1328-9.
17. Jorgensen I., Miao E.A. Pyroptotic cell death defends against intracellular pathogens. Immunol. Rev. 2015, 265(1):130-142. 10.1111/imr.12287.
18. Viganò E., Mortellaro A. Caspase-11: the driving factor for noncanonical inflammasomes. Eur. J. Immunol. 2013, 43(9):2240-2245. 10.1002/eji.201343800.
19. Hara H., Tsuchiya K., Kawamura I., Fang R., Hernandez-Cuellar E., Shen Y., Mizuguchi J., Schweighoffer E., Tybulewicz V., Mitsuyama M. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat. Immunol. 2013, 14(12):1247-1255. (Epub 2013 November 3). 10.1038/ni.2749.
20. Py B.F., Kim M.S., Vakifahmetoglu-Norberg H., Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 2013, 49(2):331-338. (Epub 2012 December 13). 10.1016/j.molcel.2012.11.009.
21. Dubyak G.R. P2X7 receptor regulation of non-classical secretion from immune effector cells. Cell. Microbiol. 2012, 14(11):1697-1706. (Epub 2012 August 24). 10.1111/cmi.12001.
22. Netea M.G., Nold-Petry C.A., Nold M.F., Joosten L.A., Opitz B., van der Meer J.H., van de Veerdonk F.L., Ferwerda G., Heinhuis B., Devesa I., Funk C.J., Mason R.J., Kullberg B.J., Rubartelli A., van der Meer J.W., Dinarello C.A. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113(10):2324-2335. (Epub 2008 December 22). 10.1182/blood-2008-03-146720.
23. Netea M.G., van de Veerdonk F.L., van der Meer J.W., Dinarello C.A., Joosten L.A. Inflammasome-independent regulation of IL-1-family cytokines. Annu. Rev. Immunol. 2015, 33:49-77. (Epub 2014 December 10). 10.1146/annurev-immunol-032414-112306.
24. Bellora F., Castriconi R., Doni A., Cantoni C., Moretta L., Mantovani A., Moretta A., Bottino C. M-CSF induces the expression of a membrane-bound form of IL-18 in a subset of human monocytes differentiating in vitro toward macrophages. Eur. J. Immunol. 2012, 42:1618-1626.
25. Bellora F., Castriconi R., Dondero A., Pessino A., Nencioni A., Liggieri G., Moretta L., Mantovani A., Moretta A., Bottino C. TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur. J. Immunol. 2014, 44:1814-1822.
26. Boraschi D., Tagliabue A. The interleukin-1 receptor family. Semin. Immunol. 2013, 25(6):394-407. (Epub 2013 November 15. Review). 10.1016/j.smim.2013.10.023.
27. Lee J.K., Kim S.H., Lewis E.C., Azam T., Reznikov L.L., Dinarello C.A. Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl. Acad. Sci. USA 2004, 101(23):8815-8820. (Epub 2004 May 25).
28. Volin M.V., Koch A.E. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J. Interferon Cytokine Res. 2011, 31(10):745-751. (Epub 2011 August 24. Review). 10.1089/jir.2011.005.
29. Reddy V.S., Harskamp R.E., van Ginkel M.W., Calhoon J., Baisden C.E., Kim I.S., Valente A.J., Chandrasekar B. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J. Cell. Physiol. 2008, 215(3):697-707.
30. Chandrasekar B., Valente A.J., Freeman G.L., Mahimainathan L., Mummidi S. Interleukin-18 induces human cardiac endothelial cell death via a novel signaling pathway involving NF-kappaB-dependent PTEN activation. Biochem. Biophys. Res. Commun. 2006, 339(3):956-963.
31. Huang H., Tindall D.J. Dynamic FOXO transcription factors. J. Cell Sci. 2007, 120(Pt 15):2479-2487.
32. Zhang H., Hile K.L., Asanuma H., Vanderbrink B., Franke E.I., Campbell M.T., Meldrum K.K. IL-18 mediates proapoptotic signaling in renal tubular cells through a Fas ligand-dependent mechanism. Am. J. Physiol. Renal. Physiol. 2011, 301(1):F171-F178. (Epub 2011 April 20). 10.1152/ajprenal.00339.2010.
33. Sims J.E. IL-1 and IL-18 receptors, and their extended family. Curr. Opin. Immunol. 2002, 14(1):117-122.
34. Yoshimoto T., Takeda K., Tanaka T., Ohkusu K., Kashiwamura S., Okamura H., Akira S., Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J. Immunol. 1998, 161(7):3400-3407.
35. Kryczek I., Wei S., Gong W., Shu X., Szeliga W., Vatan L., Chen L., Wang G., Zou W. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J. Immunol. 2008, 181(9):5842-5846.
36. Hoshino T., Yagita H., Ortaldo J.R., Wiltrout R.H., Young H.A. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur. J. Immunol. 2000, 30(7):1998-2006.
37. Yoshimoto T., Nakanishi K. Roles of IL-18 in basophils and mast cells. Allergol. Int. 2006, 55:105-113.
38. Kawayama T., Okamoto M., Imaoka H., Kato S., Young H.A., Hoshino T. Interleukin-18 in pulmonary inflammatory diseases. J. Interferon Cytokine Res. 2012, 32(10):443-449. (Epub 2012 August 17). 10.1089/jir.2012.0029.
39. Hata H., Yoshimoto T., Hayashi N., Hada T., Nakanishi K. IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1- and Th2-cytokines and IL-8. Int. Immunol. 2004, 16(12):1733-1739. (Epub 2004 October 11).
40. Mailliard R.B., Alber S.M., Shen H., Watkins S.C., Kirkwood J.M., Herberman R.B., Kalinski P. IL-18-induced CD83+ CCR7+ NK helper cells. J. Exp. Med. 2005, 202(7):941-953.
41. Madera S., Sun J.C. Cutting edge: stage-specific requirement of IL-18 for antiviral NK cell expansion. J. Immunol. 2015, 194(4):1408-1412. (Epub 2015 January 14). 10.4049/jimmunol.1402001.
42. Tsutsui H., Matsui K., Okamura H., Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol. Rev. 2000, 174(April):192-209. (Review).
43. Gutzmer R., Langer K., Mommert S., Wittmann M., Kapp A., Werfel T. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J. Immunol. 2003, 171(12):6363-6371.
44. Maxwell J.R., Yadav R., Rossi R.J., Ruby C.E., Weinberg A.D., Aguila H.L., et al. IL-18 bridges innate and adaptive immunity through IFN-{gamma} and the CD134 pathway. J. Immunol. 2006, 177(1):234-245.
45. Netea M.G., Fantuzzi G., Kullberg B.J., Stuyt R.J., Pulido E.J., McIntyre R.C., Joosten L.A., Van der Meer J.W., Dinarello C.A. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J. Immunol. 2000, 164(5):2644-2649.
46. Chijioke O., Münz C. Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front. Immunol. 2013, 11(4):365. (eCollection 2013). 10.3389/fimmu.2013.0036.
47. Iannello A., Samarani S., Debbeche O., Ahmad R., Boulassel M.R., Tremblay C., Toma E., Routy J.P., Ahmad A. Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J. Virol. 2009, 83(12):5999-6010. (Epub 2009 April 1). 10.1128/JVI.02350-08.
48. Ehlers M., Papewalis C., Stenzel W., Jacobs B., Meyer K.L., Deenen R., Willenberg H.S., Schinner S., Thiel A., Scherbaum W.A., Ullrich E., Zitvogel L., Schott M. Immunoregulatory natural killer cells suppress autoimmunity by down-regulating antigen-specific CD8+ T cells in mice. Endocrinology 2012, 153(9):4367-4379. (Epub 2012 June 25). 10.1210/en.2012-1247.
49. Terme M., Ullrich E., Aymeric L., Meinhardt K., Coudert J.D., Desbois M., Ghiringhelli F., Viaud S., Ryffel B., Yagita H., Chen L., Ḿecheri S., Kaplanski G., Pŕevost-Blondel A., Kato M., Schultze J.L., Tartour E., Kroemer G., Degli-Esposti M., Chaput N., Zitvogel L. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 2012, 72:2757-2767.
50. Terme M., Ullrich E., Aymeric L., Meinhardt K., Desbois M., Delahaye N., Viaud S., Ryffel B., Yagita H., Kaplanski G., Prévost-Blondel A., Kato M., Schultze J.L., Tartour E., Kroemer G., Chaput N., Zitvogel L. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011, 71(16):5393-5399. (Epub 2011 July 1). 10.1158/0008-5472.CAN-11-0993.
51. Fujioka N., Akazawa R., Ohashi K., Fujii M., Ikeda M., Kurimoto M. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J. Virol. 1999, 73:2401-2409.
52. Sugawara I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect. 2000, 2000:1257-1263.
53. Reading P.C., Whitney P.G., Barr D.P., Wojtasiak M., Mintern J.D., Waithman J., et al. IL-18, but not IL-12, regulates NK cell activity following intranasal Herpes Simplex virus type 1 infection. J. Immunol. 2007, 179(5):3214-3221.
54. Kinoshita M., Miyazaki H., Ono S., Seki S. Immunoenhancing therapy with interleukin-18 against bacterial infection in immunocompromised hosts after severe surgical stress. J. Leukoc. Biol. 2013, 93(5):689-698. (Epub 2013 February 13. Review). 10.1189/jlb.101250.
55. Niu Z.L., Zhang P.A., Tong Y.Q. Association of plasma interleukin-18 levels and polymorphisms in interleukin-18 gene with outcomes of hepatitis C virus infections: a meta-analysis. J. Immunoassay Immunochem. 2015, 36(3):221-232. (Review). 10.1080/15321819.2014.924418.
56. Nakamura S., Otani T., Ijiri Y., Motoda R., Kurimoto M., Orita K. IFN-gamma-dependent and independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 2000, 164(6):3330-3336.
57. Liu Y., Sato H., Hamana M., Moonan N.A., Yoneda M., Xia X., Kai C. Construction of an expression system for bioactive IL-18 and generation of recombinant canine distemper virus expressing IL-18. J. Vet. Med. Sci. 2014, 76(9):1241-1248. (Epub 2014 June 4).
58. Zorrilla E.P., Sanchez-Alavez M., Sugama S., Brennan M., Fernandez R., Bartfai T., et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc. Natl. Acad. Sci. USA 2007, 104(26):11097-11102. 10.1073/pnas.0611523104.
59. Oikawa Y., Shimada A., Kasuga A., Morimoto J., Osaki T., Tahara H., Miyazaki T., Tashiro F., Yamato E., Miyazaki J., Saruta T. Systemic administration of IL-18 promotes diabetes development in young non-obese diabetic mice. J. Immunol. 2003, 171(11):5865-5875.
60. Rothe H., Hausmann A., Casteels K., Okamura H., Kurimoto M., Burkart V., Mathieu C., Kolb H. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. J. Immunol. 1999, 163(3):1230-1236.
61. Zorrilla E.P., Conti B. Interleukin-18 null mutation increases weight and food intake and reduces energy expenditure and lipid substrate utilization in high-fat diet fed mice. Brain Behav. Immun. 2014, 37:45-53. (Epub 2013 December 6). 10.1016/j.bbi.2013.12.001.
62. Netea M.G., Joosten L.A., Lewis E., Jensen D.R., Voshol P.J., Kullberg B.J., Tack C.J., van Krieken H., Kim S.H., Stalenhoef A.F., van de Loo F.A., Verschueren I., Pulawa L., Akira S., Eckel R.H., Dinarello C.A., van den Berg W., van der Meer J.W. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 2006, 12:650-656.
63. Yang Y.S., Li X.Y., Hong J., Gu W.Q., Zhang Y.F., Yang J., Song H.D., Chen J.L., Ning G. Interleukin-18 enhances glucose uptake in 3T3-L1 adipocytes. Endocrine 2007, 32(3):297-302. (Epub 2008 February 5). 10.1007/s12020-008-9048-z.
64. Zilverschoon G.R., Tack C.J., Joosten L.A., Kullberg B.J., van der Meer J.W., Netea M.G. Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int. J. Obes. (Lond.) 2008, 32:1407-1414.
65. Novick D., Kim S.H., Fantuzzi G., Reznikov L.L., Dinarello C.A., Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127-136.
66. Kumar S., McDonnell P.C., Lehr R., Tierney L., Tzimas M.N., Griswold D.E., Capper E.A., Tal-Singer R., Wells G.I., Doyle M.L., Young P.R. Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. 2000, 275(14):10308-10314.
67. Novick D., Schwartsburd B., Pinkus R., Suissa D., Belzer I., Sthoeger Z., et al. A novel IL-18BP ELISA shows elevated serum il-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001, 14(6):334-342. 10.1006/cyto.2001.0914.
68. Hurgin V., Novick D., Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc. Natl. Acad. Sci. USA 2002, 99(26):16957-16962. (Epub 2002 December 13).
69. Paulukat J., Bosmann M., Nold M., Garkisch S., Kämpfer H., Frank S., Raedle J., Zeuzem S., Pfeilschifter J., Mühl H. Expression and release of IL-18 binding protein in response to IFN-gamma. J. Immunol. 2001, 167(12):7038-7043.
70. Fantuzzi G., Reed D., Qi M., Scully S., Dinarello C.A., Senaldi G. Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity. Eur. J. Immunol. 2001, 31(2):369-375.
71. Wittmann M., Doble R., Bachmann M., Pfeilschifter J., Werfel T., Mühl H. IL-27 regulates IL-18 binding protein in skin resident cells. PLoS ONE 2012, 7(6):e38751. (Epub 2012 June 27). 10.1371/journal.pone.003875.
72. Kim S.H., Eisenstein M., Reznikov L., Fantuzzi G., Novick D., Rubinstein M., Dinarello C.A. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA 2000, 97(3):1190-1195.
73. Reading P.C., Smith G.L. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J. Virol. 2003, 77:9960-9968.
74. Xiang Y., Moss B. IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. PNAS 1999, 96:11537-11542.
75. Dinarello C.A., Bufler P. Interleukin-37. Semin. Immunol. 2013, 25(6):466-468. (Epub 2013 November 23). 10.1016/j.smim.2013.10.004.
76. Xu W.D., Zhao Y., Liu Y. Insights into IL-37, the role in autoimmune diseases. Autoimmun. Rev. 2015, 8(August). pii: S1568-9972(15)00181-0 (Epub ahead of print). 10.1016/j.autrev.2015.08.006.
77. Bulau A.M., Nold M.F., Li S., Nold-Petry C.A., Fink M., Mansell A., Schwerd T., Hong J., Rubartelli A., Dinarello C.A., Bufler P. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc. Natl. Acad. Sci. USA 2014, 111(7):2650-2655. (Epub 2014 January 30). 10.1073/pnas.1324140111.
78. Nold M.F., Nold-Petry C.A., Zepp J.A., Palmer B.E., Bufler P., Dinarello C.A. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 2010, 11(11):1014-1022. (Epub 2010 October 10). 10.1038/ni.1944.
79. McNamee E.N., Masterson J.C., Jedlicka P., McManus M., Grenz A., Collins C.B., et al. Interleukin37 expression protects mice from colitis. Proc. Natl. Acad. Sci. USA 2011, 108(40):16711-16716. 10.1073/pnas.1111982108.
80. Nold-Petry C.A., Lo C.Y., Rudloff, Elgass K.D., Li S., Gantier M.P., Lotz-Havla A.S., Gersting S.W., Cho S.X., Lao J.C., Ellisdon A.M., Rotter B., Azam T., Mangan N.E., Rossello F.J., Whisstock J.C., Bufler P., Garlanda C., Mantovani A., Dinarello C.A., Nold M.F. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat. Immunol. 2015, 16(4):354-365. (Epub 2015 March 2). 10.1038/ni.310.
81. Li S., Neff C.P., Barber K., Hong J., Luo Y., Azam T., Palmer B.E., Fujita M., Garlanda C., Mantovani A., Kim S., Dinarello C.A. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc. Natl. Acad. Sci. USA 2015, 112(8):2497-2502. (Epub 2015 February 5). 10.1073/pnas.1424626112.
82. Lunding L., Webering S., Vock C., Schröder A., Raedler D., Schaub B., Fehrenbach H., Wegmann M. IL-37 requires IL-18Rα and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy 2015, 70(4):366-373. (Epub 2015 January 26). 10.1111/all.12566.
83. Bulek K., Swaidani S., Qin J., Lu Y., Gulen M.F., Herjan T., et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J. Immunol. 2009, 182:2601-2609.
84. Banda N.K., Vondracek A., Kraus D., Dinarello C.A., Kim S.H., Bendele A., et al. Mechanisms of Inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. 2003, 170(4):2100-2105.
85. Chattergoon M.A., Latanich R., Quinn J., Winter M.E., Buckheit R.W., Blankson J.N., Pardoll D., Cox A.L. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014, 10(5):e1004082. (eCollection 2014). 10.1371/journal.ppat.100408.
86. Guo H., Gao J., Taxman D.J., Ting J.P., Su L. HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J. Biol. Chem. 2014, 289(31):21716-21726. (Epub 2014 June 17). 10.1074/jbc.M114.566620.
87. Hernandez J.C., Latz E., Urcuqui-Inchima S. HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages. Intervirology 2014, 57(1):36-42. (Epub 2013 September 5). 10.1159/000353902.
88. Chen L., Liu J., Xu C., Keblesh J., Zang W., Xiong H. HIV-1gp120 induces neuronal apoptosis through enhancement of 4-aminopyridine-senstive outward K+ currents. PLoS ONE 2011, 6(10):e25994. (Epub 2011 October 7). 10.1371/journal.pone.002599.
89. Galloway N.L., Doitsh G., Monroe K.M., Yang Z., Muñoz-Arias I., Levy D.N., Greene W.C. Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells. Cell Rep. 2015, 12(10):1555-1563. (Epub 2015 August 28). 10.1016/j.celrep. 2015.08.01.
90. Monroe K.M., Yang Z., Johnson J.R., Geng X., Doitsh G., Krogan N.J., Greene W.C. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 2014, 343(6169):428-432. (Epub 2013 December 19). 10.1126/science.1243640.
91. Thea D.M., Porat R., Nagimbi K., Baangi M., St Louis M.E., Kaplan G., Dinarello C.A., Keusch G.T. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1. Ann. Intern. Med. 1996, 124:757-762.
92. Appay V., Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol. 2008, 214:231-241.
93. Ahmad R., Sindhu S.T., Toma E., Morisset R., Ahmad A. Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. J. Virol. 2002, 76(24):12448-12456.
94. Torre D., Speranza F., Martegani R., Pugliese A., Castelli F., Basilico C., Biondi G. Circulating levels of IL-18 in adult and paediatric patients with HIV-1 infection. AIDS 2000, 14(14):2211-2212.
95. Song W., Wilson C.M., Allen S., Wang C., Li Y., Kaslow R.A., Tang J. Interleukin 18 and human immunodeficiency virus type I infection in adolescents and adults. Clin. Exp. Immunol. 2006, 144(1):117-124.
96. Torre D., Pugliese A. Interleukin-18: a proinflammatory cytokine in HIV-1 infection. Curr. HIV Res. 2006, 4(4):423-430. (Review).
97. Sailer C.A., Pott G.B., Dinarello C.A., Whinney S.M., Forster J.E., Larson-Duran J.K., Landay A., Al-Harthi L., Schooley R.T., Benson C.A., Judson F.N., Thompson M., Palella F.J., Shapiro L. Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon-gamma levels. J. Infect. Dis. 2007, 195(5):734-738. (Epub 2007 January 18).
98. Stylianou E., Bjerkeli V., Yndestad A., Heggelund L., Waehre T., Damås J.K., Aukrust P., Frøland S.S. Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients. Clin. Exp. Immunol. 2003, 132(3):462-466. (in vitro Il-18 upregulated CXCR4 and TRAIL on PBMC).
99. Wiercinska-Drapalo A., Jaroszewicz J., Flisiak R., Prokopowicz D. Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes Infect. 2004, 6(14):1273-1277.
100. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106(10):3483-3489.
101. Liang D., Ma W., Yao C., Liu H., Chen X. Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis. Cell. Mol. Immunol. 2006, 3(4):303-306.
102. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., Vogel W., et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J. Clin. Immunol. 2002, 22(6):331-337.
103. Shao X.T., Feng L., Gu L.J., Wu L.J., Feng T.T., Yang Y.M., Wu N.P., Yao H.P. Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clin. Exp. Med. 2009, 9(3):215-221. (Epub 2009 February 19). 10.1007/s10238-009-0036-2.
104. Novick D., Elbirt D., Miller G., Dinarello C.A., Rubinstein M., Sthoeger Z.M. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J. Autoimmun. 2010, 34(2):121-126. (Epub 2009 August 22). 10.1016/j.jaut.2009.08.002.
105. Dinarello C.A., Novick D., Kim S., Kaplanski G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 2013, 8(4):289. 10.3389/fimmu.2013.00289.
106. Iannello A., Boulassel M.R., Samarani S., Tremblay C., Toma E., Routy J.P., Ahmad A. HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. J. Infect. Dis. 2010, 201(4):608-617. 10.1086/650314.
107. Stylianou E., Aukrust P., Kvale D., Müller F., Frøland S. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression: down-regulatory effect of potent anti-retroviral therapy. Clin. Exp. Immunol. 1999, 116:115-120.
108. Wiercinska-Drapalo A., Flisiak R., Jaroszewicz J., Prokopowicz D. Increased plasma transforming growth factor-b1 is associated with disease progression in HIV-1-infected patients. Viral Immunol. 2004, 17:109-113.
109. Chehimi J., Starr S.E., Frank I., D'Andrea A., Ma X., MacGregor R.R., Sennelier J., Trinchieri G. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 1994, 179(4):1361-1366.
110. Sgarbanti M., Remoli A.L., Marsili G., Ridolfi B., Borsetti A., Perrotti E., Orsatti R., Ilari R., Sernicola L., Stellacci E., Ensoli B., Battistini A. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J. Virol. 2008, 82(7):3632-3641. (Epub 2008 January 23). 10.1128/JVI.00599-07.
111. Torres R.A., Lewis W. Aging and HIV/AIDS: pathogenetic role of therapeutic side effects. Lab. Invest. 2014, 94(2):120-128. (Epub 2013 December 16). 10.1038/labinvest.2013.142.
112. Kim S.R., Kim D.I., Kim S.H., Lee H., Lee K.S., Cho S.H., Lee Y.C. NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis. 2014, 30(5):e1498. 10.1038/cddis.2014.460.
113. Fowler B.J., Gelfand B.D., Kim Y., Kerur N., Tarallo V., Hirano Y., Amarnath S., Fowler D.H., Radwan M., Young M.T., Pittman K., Kubes P., Agarwal H.K., Parang K., Hinton D.R., Bastos-Carvalho A., Li S., Yasuma T., Mizutani T., Yasuma R., Wright C., Ambati J. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science 2014, 346(6212):1000-1003. 10.1126/science.1261754.
114. Reddy S., Comai L. Lamin A, farnesylation and aging. Exp. Cell Res. 2012, 318(1):1-7. (Epub 2011 August 16). 10.1016/j.yexcr.2011.08.009.
115. Højen J.F., Rasmussen T.A., Andersen K.L., Winckelmann A.A., Laursen R.R., Gunst J.D., Møller H.J., Fujita M., Østergaard L., Søgaard O.S., Dinarello C.A., Tolstrup M. Interleukin-37 expression is increased in chronic HIV 1-infected individuals and is associated with inflammation and the size of the total viral reservoir. Mol. Med. 2015, 14(21):337-345. 10.2119/molmed.2015.00031.
116. Iannello A., Samarani S., Debbeche O., Tremblay C., Toma E., Boulassel M.R., Routy J.P., Ahmad A. Role of interleukin-18 in the development and pathogenesis of AIDS. AIDS Rev. 2009, 11(3):115-125. (Review).
117. Iannello A., Samarani S., Debbeche O., Boulassel M.R., Tremblay C., Toma E., Routy J.P., Ahmad A. Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions. Curr. HIV Res. 2010, 8(2):147-164. (Review).
118. Segat L., Bevilacqua D., Boniotto M., Arraes L.C., de Souza P.R., de Lima Filho J.L., Crovella S. IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population. Immunogenetics 2006, 58(5-6):471-473. (Epub 2006 May 5).
119. Kaizu M., Ami Y., Nakasone T., Sasaki Y., Izumi Y., Sato H., Takahashi E., Sakai K., Shinohara K., Nakanishi K., Honda M. Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV. Virology 2003, 313(1):8-12.
120. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe?. Immunity 2010, 32(3):300-302. 10.1016/j.immuni.2010.03.010.
121. Allam O., Samarani S., Ahmad A. Microbial translocation and AIDS-associated lymphomas: crux of the problem. AIDS 2013, 27(3):477-478. 10.1097/QAD.0b013e32835cba91.
122. Chandrasekar B., Patel D.N., Mummidi S., Kim J.W., Clark R.A., Valente A.J. Interleukin-18 suppresses adiponectin expression in 3T3-L1 adipocytes via a novel signal transduction pathway involving ERK1/2-dependent NFATc4 phosphorylation. Mol. Med. 2014, 12(20):221-229. 10.2119/molmed.2014.00034.
123. Ballak D.B., Stienstra R., Tack C.J., Dinarello C.A., van Diepen J.A. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine 2015, 75(2):280-290. (Epub 2015 July 17). 10.1016/j.cyto.2015.05.005.
124. Falasca K., Manigrasso M.R., Racciatti D., Zingariello P., Dalessandro M., Ucciferri C., Mancino P., Marinopiccoli M., Petrarca C., Conti P., Pizzigallo E., Guagnano M.T., Vecchiet J. Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Ann. Clin. Lab. Sci. 2006, 36(1):59-66. (Winter).
125. Oikawa Y., Shimada A., Kasuga A., Morimoto J., Osaki T., Tahara H., Miyazaki T., Tashiro F., Yamato E., Miyazaki J., Saruta T. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J. Immunol. 2003, 171(11):5865-5875.
126. Nicoletti F., Di Marco R., Papaccio G., Conget I., Gomis R., Bernardini R., Sims J.E., Shoenfeld Y., Bendtzen K. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL-18-binding protein: Fc construct. Eur. J. Immunol. 2003, 33(8):2278-2286.
127. Sennello J.A., Fayad R., Pini M., Gove M.E., Ponemone V., Cabay R.J., Siegmund B., Dinarello C.A., Fantuzzi G. Interleukin-18, together with interleukin-12, induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice. Proc. Natl. Acad. Sci. USA 2008, 105(23):8085-8090. (Epub 2008 May 30). 10.1073/pnas.0804091105.
128. Badimon L. Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis. Cardiovasc. Res. 2012, 96(2):172-175. discussion 176-180 (Epub 2012 August 25). 10.1093/cvr/cvs22.
129. Elhage R., Jawien J., Rudling M., Ljunggren H.G., Takeda K., Akira S., Bayard F., Hansson G.K. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 2003, 59(1):234-240.
130. Whitman S.C., Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res. 2002, 90(2):E34-E38.
131. Mallat Z., Corbaz A., Scoazec A., Besnard S., Lesèche G., Chvatchko Y., Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104(14):1598-1603.
132. O'Brien L.C., Mezzaroma E., Van Tassell B.W., Marchetti C., Carbone S., Abbate A., Toldo S. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol. Med. 2014, 12(20):221-229. 10.2119/molmed.2014.00034.
133. Kulasekaram R., Peters B.S., Wierzbicki A.S. Dyslipidemia and cardiovascular risk in HIV infection. Curr. Med. Res. Opin. 2005, 21(11):1717-1725.
134. Patel A.A., Budoff M.J. Coronary artery disease in patients with HIV infection. Am. J. Cardiovasc. Drugs 2015, 15(2):81-87. 10.1007/s40256-015-0105-8.
135. Alboni S., Cervia D., Sugama S., Conti B. Interleukin 18 in the CNS. J. Neuroinflam. 2010, 7:9. (Review). 10.1186/1742-2094-7-9.
136. Jenabian M.A., El-Far M., Vyboh K., Kema I., Costiniuk C.T., Thomas R., Baril J.G., LeBlanc R., Kanagaratham C., Radzioch D., Allam O., Ahmad A., Lebouché B., Tremblay C., Ancuta P., Routy J.P. Montreal primary infection and slow progressor study groups. J. Infect. Dis. 2015, 212(3):355-366. (Epub 2015 January 23. Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection). 10.1093/infdis/jiv03.
137. Liu L., Chan C. The role of inflammasome in Alzheimer's disease. Ageing Res. Rev. 2014, 15:6-15. (Epub 2014 February 19). 10.1016/j.arr.2013.12.007.
138. von Giesen H.J., Jander S., Köller H., Arendt G. Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease. J. Neurovirol. 2004, 10(6):383-386.
139. Ipp H., Zemlin A.E., Erasmus R.T., Glashoff R.H. Role of inflammation in HIV-1 disease progression and prognosis. Crit. Rev. Clin. Lab. Sci. 2014, 51(2):98-111. (Epub 2014 January 30). 10.3109/10408363.2013.865702.